AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
03 mai 2024 03h00 HE
|
AAVantgarde Bio
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
24 avr. 2024 02h00 HE
|
AAVantgarde Bio
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
23 avr. 2024 02h00 HE
|
AAVantgarde Bio
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
06 juin 2023 08h00 HE
|
AAVantgarde Bio
- Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a...